Share

December 01, 2020; 95 (22) ArticleOpen Access

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Jozef Hanes, Andrej Kovac, Hlin Kvartsberg, Eva Kontsekova, Lubica Fialova, Stanislav Katina, Branislav Kovacech, Eva Stevens, Jakub Hort, Martin Vyhnalek, Lynn Boonkamp, Michal Novak, Henrik Zetterberg, Oskar Hansson, Philip Scheltens, Kaj Blennow, Charlotte E. Teunissen, Norbert Zilka
First published September 24, 2020, DOI: https://doi.org/10.1212/WNL.0000000000010814
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
1679

Share

Abstract

Objective To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls.

Methods We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from 3 cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy participants (n = 44).

Results The p-tau T217 assay (cutoff 242 pg/mL) identified patients with AD with accuracy of 90%, with 78% positive predictive value (PPV), 97% negative predictive value (NPV), 93% sensitivity, and 88% specificity, compared favorably with p-tau T181 ELISA (52 pg/mL), showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity, and 97% sensitivity. The assay distinguished patients with AD from age-matched healthy controls (cutoff 163 pg/mL, 98% sensitivity, 93% specificity), similarly to p-tau T181 ELISA (cutoff 60 pg/mL, 96% sensitivity, 86% specificity). In patients with AD, we found a strong correlation between p-tau T217 and p-tau T181, total tau and β-amyloid 40, but not β-amyloid 42.

Conclusions This study demonstrates that p-tau T217 displayed better diagnostic accuracy than p-tau T181. The data suggest that the new p-tau T217 assay has potential as an AD diagnostic test in clinical evaluation.

Classification of evidence This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes patients with AD from patients with other dementias and healthy controls.

Glossary

Aβ=
β-amyloid;
AD=
Alzheimer disease;
AUC=
area under the curve;
bvFTD=
behavioral variant of frontotemporal dementia;
CBD=
corticobasal degeneration;
CI=
confidence interval;
FTD=
frontotemporal dementia;
LLOQ=
lower limit of quantification;
nvPPA=
nonfluent variant of primary progressive aphasia;
p-tau=
phosphorylated tau;
PSP=
progressive supranuclear palsy;
svPPA=
semantic variant of primary progressive aphasia;
t-tau=
total tau

In Alzheimer disease (AD), there is a need for biomarkers that reflect the key pathophysiology of the disease: neurodegeneration and β-amyloid (Aβ) and tau protein pathology.1 Over the past 2 decades, significant efforts have been made to identify in vivo brain indicators and fluid-based biomarkers for preclinical and clinical AD.2,–,4

In 2018, the National Institute on Aging and Alzheimer's Association Research Framework shifted the definition of AD in living people from a syndromal to a biological construct.5 The new research framework defines AD by using a variety of biomarkers, which are grouped into those of Aβ deposition, pathologic tau protein, and neurodegeneration (A/T/N).5

Recently, a new biomarker for AD has been reported: tau phosphorylated at Thr217 (p-tau T217). It has been shown that p-tau T217 species (quantified as pT217/T217 ratio) highly correlate with amyloid lesions in the brain, cognitive decline, and tau PET imaging in AD.6,–,8 In physiologic conditions, p-tau T217 species display rapid turnover in the extracellular space.8

We developed a novel immunoassay to detect p-tau T217 in the CSF, and subsequently undertook this study to (1) evaluate the sensitivity and specificity of the p-tau T217 assay using AD and non-AD CSF samples from 3 international cohorts of patients; (2) compare its sensitivity and specificity with standard CSF measures (particularly with total tau [t-tau], p-tau T181, Aβ40, and Aβ42); and (3) assess the relationship between the levels of p-tau T217 with the above-mentioned standard CSF biomarkers.

Methods

Standard protocol approvals, registrations, and participant consents

Written informed consent was obtained from all patients (or guardians of patients) participating in the study. All protocols were approved by the ethical committees of Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands; Lund University, Sweden; or Motol University Hospital, Prague, Czech Republic.

Assay development and validation

Preparation of hybridoma cell lines expressing DC2E7 and DC2E2 antibodies and their purification

We prepared DC2E7 and DC2E2 hybridoma cell lines as described previously.9 To generate the DC2E7 and DC2E2 antibodies, we immunized Balb/c mice with either sarkosyl-insoluble tau (PHF-tau) isolated from AD brain (frontal cortex, Braak stage VI, Netherlands brain bank) or recombinant human tau protein (aa 1–242 of the longest tau isoform). Antibodies were purified using protein G affinity chromatography by Äkta Avant Purifier (both GE Healthcare, Chicago, IL).

Analyzing of both antibodies showed that DC2E7 recognizes p-tau protein, while DC2E2 is a pan-tau antibody recognizing a proline-rich domain of tau protein. To define the exact phosphoepitope for DC2E7, we generated mutated forms of tau 2N4R with single point mutations in which serine and threonine residues were replaced by alanine. The immunoblotting analysis showed that antibody DC2E7 recognized all p-tau proteins carrying the point mutations except for Thr217Ala. This suggests that phospho-threonine at position 217 creates a key part of the epitope recognized by antibody DC2E7 (supplemental figure 1, data available from Dryad, doi.org/10.5061/dryad.tdz08kpwz).

p-tau T217 Simoa assay

We set up the p-tau T217 assay in the highly sensitive format of a single molecule array (Simoa) digital ELISA, using an HD-1 Analyzer (Quanterix, Billerica, MA). Reagents for the assay were prepared according to the Quanterix Homebrew Assay Development Guide with the following details: we used DC2E7 antibody as a capture antibody and DC2E2 antibody as a detector antibody; the capture antibody DC2E7 was coupled to magnetic beads (Quanterix) at a concentration of 0.5 mg/mL according to the Simoa alternate bead conjugation protocol (2017); the detector antibody DC2E2 was prepared by biotinylation of DC2E2, where 120-fold excess of biotin, EZ‐Link NHS‐PEG4‐Biotin (Thermo Fisher Scientific, Waltham, MA; 21329), over antibody concentration was used.

We prepared the pT217 calibrator as a synthetic peptide containing both epitopes of the DC2E7 and DC2E2 antibodies. This peptide was dissolved in a calibrator diluent at a concentration of 2 µg/mL, aliquoted and stored at −80°C. The calibrator was diluted in a calibrator diluent (20 mM sodium phosphate pH 7.4, 137 mM NaCl, 2.7 mM KCl, 2% bovine serum albumin) in serial 1.6-fold dilutions starting from 2,000 pg/mL, followed by 1,250, 781.25, 488.28, 305.18, 190.73, 119.21, 74.51, and 0 pg/mL. The prepared calibrator concentrations were mixed in a 3:1 ratio with a sample diluent (80 mM sodium phosphate pH 7.4, 548 mM NaCl, 10.8 mM KCl, 0.04% casein, and 0.4% Tween 20). The CSF samples were diluted with a sample diluent in the same way as described for the calibrator (3 volumes CSF +1 volume sample diluent). The assay was performed as a 2-step assay 1.0 according to the manufacturer's recommendation (Quanterix).

Validation of the assay: experimental setup

The validation was conducted in an open-label fashion at the Department of Clinical Chemistry, Amsterdam, the Netherlands. The protocol for p-tau T217 detection and quantitation was applied to Simoa using the HD-1 Analyzer. The assay's sensitivity, precision, linearity, parallelism, and recovery were analyzed as previously described.10 To identify the lower limit of quantification (LLOQ), 16 blank samples (240 μL calibrator diluent + 80 μL sample diluent) were measured. The LLOQ (concentration) was based on a signal of 10 SDs above the mean of the 16 blank samples (using the calibration curve). Precision was determined by calculating the intra-assay, interassay, and intraplate reproducibility. For the dilution linearity, 3 different CSF samples were spiked with 3,000 pg/mL of pT217 calibrator and diluted 2-fold until below the theoretical LLOQ. To assess parallelism, 5 different CSF samples were diluted 2-fold. To determine sample recovery, 4 different CSF samples were spiked with low (200 pg/mL), medium (500 pg/mL), or high (1,500 pg/mL) concentrations of the pT217 calibrator. Phosphate-buffered saline was spiked as a reference.

Clinical cohorts

Participants

The first cohort from the ongoing Amsterdam Dementia Cohort included 88 participants with age-matched controls: AD, nonfluent variant of primary progressive aphasia (nvPPA), semantic variant of primary progressive aphasia (svPPA), behavioral variant of frontotemporal dementia (bvFTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) (table 1). All participants visited the memory clinic at VU University Medical Center Amsterdam for extensive clinical evaluations that consisted of neurologic, physical, and neuropsychological evaluations, biomarker analyses in CSF, EEG, and brain MRI.11

View this table:
Table 1

Characteristics of the study cohorts

The second cohort included 44 cognitively normal elderly participants and 47 patients with AD recruited from the Skåne University Hospital, Sweden. The inclusion criteria for the cognitively normal elderly participants were age ≥60 years, a Mini-Mental State Examination score of 28–30 points at the screening visit, absence of cognitive symptoms as evaluated by a physician, fluency in Swedish, and not fulfilling the criteria of mild cognitive impairment or any dementia. Patients with AD were required to meet the criteria for probable AD as defined by the National Institute of Neurologic and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association.12

The third cohort included patients from the Czech Brain Aging Study Plus Cohort. In total, 11 patients with probable non-AD tauopathy were included: nvPPA (n = 5), PSP (n = 3), and CBD (n = 3). Patients with nvPPA fulfilled imaging criteria for nvPPA as described by Gorno-Tempini et al.13 Patients with PSP were diagnosed with probable PSP with Richardson syndrome14 and patients with CBD fulfilled the criteria for probable sporadic CBS.15

CSF sampling and core AD CSF biomarkers

CSF was handled in compliance with standard recommendations.16 All the samples were collected and stored in polypropylene tubes at −80°C according to lumbar puncture consensus protocols.17 Aβ42, t-tau, p-tau T181, and Aβ40 were measured by Fujirebio (Tokyo, Japan) Innotest ELISA assays. For the analysis of Aβx-42/Aβx-40 ratio in cohort 2, a Meso Scale Discovery (Rockville, MD) Abeta Triplex assay was used. Cohorts 1 and 3 were analyzed in Amsterdam and cohort 2 was analyzed in Gothenburg. All analyses were conducted in an open-label fashion.

Immunohistochemical staining

For immunohistochemistry, the following brain areas were used: hippocampus and entorhinal cortex from AD (Braak stage VI, n = 3), frontotemporal dementia (FTD) (Pick disease, n = 3), control brain (Braak stage I, n = 3), and prodromal AD (Braak stage III, n = 3); caudate nucleus from CBD (n = 3); and putamen/caudate nucleus from PSP (n = 3). The brain tissue paraffin blocks were obtained from the Amsterdam brain bank.

The brain blocks embedded in paraffin were cut on a microtome (Leica [Newcastle, UK] RM2255) to obtain 8-μm-thick sections. The sections were placed on HistoBond slides (Marienfeld, Germany). Immunohistochemistry sections were pretreated with formic acid and heat (autoclave, 121°C, 20 minutes), followed by overnight incubation with primary antibodies (AT8 1:1,000, DC2E7 1:10,000, DC2E2 1:200). All sections were incubated with anti-mouse biotinylated secondary antibody at room temperature for 1 hour and with avidin-biotin peroxidase complex for 1 hour. The immunoreaction was visualized with VIP (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA) and counterstained with methyl green (Vector Laboratories).

Statistical analysis

First, the performance of the diagnostic assay was evaluated based on diagnostic accuracy, positive predictive value, negative predictive value, sensitivity, and specificity. False-positive fraction (1 − specificity) and true-positive fraction (sensitivity) were calculated. Based on this result, area under the curve (AUC), 95% confidence interval (CI) for AUC, and optimal threshold were calculated.18 Where necessary, a linear approximation to calculate specificity and sensitivity for prespecified thresholds was used. The equality of AUC curves using the 2‐sample Wald Z test was also tested.19 Second, the differences in means of p-tau T217 between AD and other diagnoses were assessed using a bootstrap 2-sample t test (the number of bootstrap samples was 10,000) followed by Bonferroni multiple adjustment of p values. The differences in means of p-tau T217 between patients with AD and controls were assessed using a bootstrap 2-sample t test (number of bootstrap samples was 10,000). The effect size Cohen d and its empirical Wald 95% CI was calculated using variance stabilizing transformation.20 Finally, the association between various CSF biomarkers was characterized by Pearson product-moment correlation coefficient and tested using Fisher Z test.21 All alternative hypotheses were 2-sided and statistical tests were performed at significance level equal to 0.05.

Primary research question

Does the p-tau T217 assay distinguish AD dementia from other dementias and healthy controls? This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes AD from other dementias and healthy controls.

Data availability

Anonymized data will be shared on request from qualified investigators.

Results

Validation of the p-tau T217 ultrasensitive immunoassay for human CSF

LLOQs based on 16 blank values were calculated to be 184.4 pg/mL. The mean parallelism of all 5 samples was 86%. Two out of 5 CSF samples fell within the acceptable range (85%–115%) and were thus parallel to the pT217 calibrator. The other 3 CSF samples were just outside the criteria of 85%–115% (81%, 82%, and 76%). The mean recovery of 3 CSF samples was 116% (low 110%, medium 116%, high 123%), just outside the predefined criteria of 85%–115%, meaning that there was almost no difference between the sample matrix and calibrator diluent. The assay was linear between a 2- and 16-fold dilution and no hook effect was observed. The precision of the assay was determined by means of the repeatability (intra-assay; 3.0%), intermediate precision (interassay; 10.3%), and within-plate reproducibility (intraplate; 3.4%) (supplemental table 1, data available from Dryad, doi.org/10.5061/dryad.tdz08kpwz). The results showed a robust performance of the assay. Overall, we concluded that the assay for p-tau T217 on the Simoa HD-1 Analyzer is suitable for the measurement of p-tau T217 in human CSF samples.

Monoclonal antibodies DC2E2 and DC2E7 recognize pathology in human AD brain and tauopathies

Neither DC2E2 nor DC2E7 recognized normal tau in the hippocampus of healthy controls fulfilling criteria for Braak stage I (figure 1A). In patients in the prodromal stage of AD (Braak stage III), the antibodies identified neurofibrillary tangles, neuropil threads, and neuritic plaques distributed mainly in the hippocampus and entorhinal and transentorhinal cortex (figure 1C). Finally, in late stage AD (Braak stage VI), the antibodies recognized extensive tau pathology in the hippocampus (figure 1E) and other cortical areas.

Figure 1
Figure 1 Monoclonal antibodies pathology recognition in normal brain, prodromal stage, and Alzheimer disease (AD)

Monoclonal antibodies DC2E2 and DC2E7 do not recognize tau in a normal brain (A and B, Braak stage I). In the prodromal stage (C and D, Braak stage III) and full-blown AD (E and F, Braak stage VI), both antibodies identify neurofibrillary pathology. They stain neurofibrillary tangles, neuropil threads, and neuritic plaques. Bar = 100 µm.

In addition to AD (figure 2, A and B; higher magnification M), both DC2E7 and DC2E2 recognized tau pathology in other tauopathies, including Pick disease, CBD, and PSP (figure 2; D and E, higher magnification N; G and H, higher magnification O; J and K). The antibodies displayed the same staining pattern and the same type and load of tau pathology as monoclonal antibody AT8, which is considered to be the gold standard for histopathologic staining22 (figure 2, C, F, I, and L).

Figure 2
Figure 2 Monoclonal antibodies pathology recognition in Alzheimer disease (AD), frontotemporal dementia (FTD), and corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP)

Monoclonal antibodies DC2E7 and DC2E2 recognized neurofibrillary pathology in the hippocampus of patients with AD (A and B), Pick bodies in the dentate gyrus of patients with FTD (D and E), and glial tau pathology in caudate nucleus of patients with CBD (G and H) or PSP (J and K). AT8 was used as a control for histopathologic staining (C, F, I, and L). Higher magnification of tau pathology in AD (M), Pick disease (N), and CBD (O). Bar = 200 µm (A–L), 50 µm (M–O).

The p-tau T217 ultrasensitive immunoassay differentiates AD from FTD

We measured p-tau T217 concentration in CSF from patients with nvPPA, svPPA, bvFTD, PSP, and CBD (cohorts 1 and 3; figure 3A). The p-tau T217 assay discriminated between AD and non-AD neurodegenerative disorders (cutoff 242 pg/mL, AUC 0.91 [95% CI 0.80, 0.96], with accuracy of 90%, with 78% PPV, 97% NPV, 88% specificity [95% CI 0.79, 0.98], and 93% sensitivity [95% CI 0.78, 0.99]) compared to p-tau T181 ELISA (figure 3B) (cutoff 52 pg/mL, AUC 0.94 [95% CI 0.84, 0.98], showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity [95% CI 0.44, 0.99], and 97% sensitivity [95% CI 0.89, 0.99]). There was no statistically significant difference in AUCs between p-tau T217 and p-tau T181 (p value = 0.912) (supplemental figure 2, data available from Dryad, doi.org/10.5061/dryad.tdz08kpwz).

Figure 3
Figure 3 CSF phosphorylated tau (p-tau) T217 and p-tau T181 levels

CSF p-tau T217 (A) and p-tau T181 (B) levels in Alzheimer disease (AD), behavioral variant of frontotemporal dementia (bvFTD), nonfluent variant of primary progressive aphasia (nvPPA), semantic variant of primary progressive aphasia (svFTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) The lines indicate cutoff values (p-tau T217, 242 pg/mL; p-tau T181, 184 pg/mL). CSF samples obtained from cohorts 1 and 3.

Comparison of means showed that the assay significantly differentiated AD and nvPPA (p < 0.0001; Cohen d 1.433, 95% CI 0.758, 2.171), svPPA (p < 0.0001; Cohen d 1.469, 95% CI 0.714, 2.296), bvFTD (p < 0.0001; Cohen d 1.586, 95% CI 0.822, 2.426), PSP (p < 0.0001; Cohen d 1.745, 95% CI 1.105, 2.455), and CBD (p < 0.0001, Cohen d 1.452; 95% CI 0.79, 2.177).

The p-tau T217 ultrasensitive immunoassay differentiates AD from controls

Further, we aimed to prove the diagnostic value of the assay to distinguish individuals with AD from healthy individuals. The p-tau T217 immunoassay was used to analyze CSF samples from patients with AD (n = 47) and control individuals (n = 44) (cohort 2). We found that the assay distinguished patients with AD from healthy individuals with very high sensitivity and specificity (cutoff 162.8 pg/mL, AUC 0.98 [95% CI 0.91, 0.99], sensitivity 98% [95% CI 0.88, 0.99], specificity 93% [95% CI 0.85, 0.99]; figure 4A). In comparison, p-tau T181 ELISA (cutoff 60 pg/mL, AUC 0.98 [95% CI 0.91, 0.99]), currently considered one of the best biomarkers for AD, showed 98% sensitivity (95% CI 0.88,0.99) and 86% specificity (95% CI 0.76, 0.99) (figure 4B). There was no statistically significant difference in AUCs between p-tau T217 and p-tau T181 (p = 0.574). Mean comparison showed that the p-tau T217 assay significantly differentiated between AD and controls (p < 0.0001; Cohen d 2.160, 95% CI 1.663, 2.701). Other commonly used CSF biomarkers for AD—t-tau, Aβ42, Aβ42/Aβ40 ratio, and p-tau T217/t-tau ratio—showed worse diagnostic performance than p-tau pT217 alone (figure 4, C–F).

Figure 4
Figure 4 Phosphorylated tau (p-tau) T217, p-tau T181, total tau (t-tau), and β-amyloid (Aβ) levels

Levels of p-tau T217 (A), p-tau T181 (B), t-tau (C), ratio p-tau T217/t-tau (D), Aβ42 (E), and ratio Aβ42/40 (F) in Alzheimer disease (AD) and controls. CSF samples obtained from cohort 2.

The amount of p-tau T217 correlates with that of p-tau T181, t-tau, and Aβ40 but not with Aβ42

In the second cohort, we found a strong correlation between p-tau T217 and p-tau T181 (figure 5A, r = 0.941, 95% CI 0.896, 0.967, p < 0.0001) and between p-tau T217 and t-tau (figure 5B, r = 0.902, 95% CI 0.829, 0.944, p < 0.0001) in AD. Interestingly, we observed a correlation between p-tau T217 and Aβ40 (figure 5C, r = 0.617, 95% CI 0.402, 0.768, p < 0.0001) but not between p-tau T217 and Aβ42 (figure 5D, r = 0.131, 95% CI −0.162, 0.403, p = 0.380) in AD. The correlation between p-tau T217 and other tau CSF biomarkers was weaker in healthy individuals: between p-tau T217 and p-tau T181 (figure 5A, r = 0.787, 95% CI 0.640, 0.879, p < 0.0001), and between p-tau T217 and t-tau (figure 5B, r = 0.541, 95% CI 0.290, 0.722, p = 0.0001). We did not find any correlations between p-tau T217 and Aβ40 (figure 5C, r = 0.235, 95% CI −0.066, 0.497, p = 0.125) or between p-tau T217 and Aβ42 (figure 5D, r = −0.126, 95% CI −0.407, 0.178, p = 0.419) in healthy individuals.

Figure 5
Figure 5 Correlations between phosphorylated tau (p-tau) T217 and p-tau T181, total tau (t-tau), and β-amyloid (Aβ)

Correlation between p-tau T217 and p-tau T181 (A), t-tau (B), Aβ40 (C), and Aβ42 (D) in Alzheimer disease (AD) and controls. CSF samples obtained from cohort 2.

Discussion

Previous studies have demonstrated that CSF p-tau T217 could potentially be a key biomarker to monitor tau pathology in AD pathophysiology, and that its role might differ from other p-tau biomarkers.6,7 In this study, we introduced a novel immunoassay, detecting p-tau T217 in CSF, which is based on the highly sensitive Simoa technology. Our results show that the assay discriminates between AD and other neurodegenerative dementias with high specificity and sensitivity, and demonstrates better diagnostic accuracy than p-tau T181 assay. This is in line with recent study on the new CSF p-tau T217 assay based on the MSD (Meso Scale Discovery) platform, where the authors showed better diagnostic performance of the assay when comparing with p-tau T181.23 Moreover, the same study revealed that the correlations with tau PET tracer [18F]flortaucipir were consistently higher for p-tau217 than p-tau181 and that [18F]flortaucipir retention was more related to longitudinal changes in p-tau217 than in p-tau181. Similarly, by using the quantitative mass spectrometry approach, Barthelemy et al.24 demonstrated that pT217 differentiated between AD and other neurodegenerative diseases with higher specificity and sensitivity than pT181. The better discriminatory potency of p-tau T217 for AD might be attributed to its ability to reflect both amyloid and tau pathologic pathways. It has been reported that increased p-tau T217 levels in CSF are related to the brain amyloid load–positive participants already at the preclinical stage, further supporting that this biomarker is AD-specific.6 The specificity of T217 tau phosphorylation change for AD surpasses other p-tau sites such as T181, S199, S202, and T205.6 These data suggest that p-tau T217 represents a promising AD biomarker.

The assay also distinguishes patients with AD from age-matched healthy controls, which is in agreement with mass spectrometry data on p-tau T217.24 Low levels of p-tau T217 in healthy controls could be caused by rapid degradation (or dephosphorylation) of tau species phosphorylated at this particular position. Indeed, one study has demonstrated that phosphorylation of tau on T217 had the most robust effect on shortening tau half-life in physiologic conditions.8

When investigating the relationship between the different biomarkers in patients with AD, p-tau T217 showed a strong correlation with t-tau, p-tau T181, and Aβ40, but not with Aβ42. It was hypothesized that Aβ42 is toxic to neurons, while Aβ40 is more strongly associated with progressive neuronal degeneration.25 The strong correlation between p-tau T217, t-tau, p-tau T181, and Aβ40 suggests that these proteins may be released from neurons in a coordinated fashion, perhaps in relation to neuronal activity, as has been suggested.26,27

Interestingly, our p-tau T217 assay discriminates AD from FTD, despite the fact that p-tau T217 was present in brain tissues of both AD and FTD. The p-tau T217 species were found to be present in all types of neurofibrillary lesions (neurofibrillary tangles, neuropil threads, dystrophic neurites, and neuritic plaques), but also in glial tau pathology (PSP, CBD) and in Pick bodies (FTD). Although our findings indicate that p-tau T217 species are involved in the developing tau pathology in neurons and glial cells in various human tauopathies, the CSF levels of p-tau T217 species are elevated almost exclusively in AD.

The potential limitation of our study could be the small sample size. Results should be replicated in larger cohorts ideally characterized by both amyloid and tau PET imaging and validated in routine clinical practice. In order to introduce p-tau T217 assay in clinical routine practice, the technology should undergo a structured assessment to evaluate its benefit in terms of clinical utility and cost-effectiveness.

Our novel immunoassay for quantification of p-tau T217 in the CSF demonstrates that the assay is highly specific for AD and seems superior to the p-tau T181 assay in AD diagnostic classifications. In the future, the assay can potentially be used for diagnostic purposes as well as for patient stratification and enrichment of target populations in clinical trials for disease-modifying therapies.

Study funding

J. Hanes and M.V. are supported by MH CZ–DRO, Motol University Hospital, Prague, Czech Republic (00064203), Institutional Support of Excellence 2, LF UK (grant 699012), and Ministry of Health of the Czech Republic (grant 19-04-00560). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018–02532), the European Research Council (681712), the UK Dementia Research Institute at UCL, and a grant (ALFGBG-720931) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement. K.B. is supported by the Swedish Research Council (2017-00915), the Swedish Alzheimer Foundation (AF-742881), Hjärnfonden, Sweden (FO2017-0243), and a grant (ALFGBG-715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement. Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network, JPND), Health Holland, the Dutch Research Council (ZonMW), The Weston Brain Institute, and Alzheimer Netherlands.

Disclosure

J. Hanes, A. Kovac, E.Kontsekova, and L. Fialova report no disclosures relevant to the manuscript; they are full-time employees of AXON Neuroscience R&D Services SE. S. Katina reports no disclosures relevant to the manuscript; he is a full-time employee of AXON Neuroscience CRM Services SE. B. Kovacech and E. Stevens report no disclosures relevant to the manuscript; they are full-time employees of AXON Neuroscience R&D Services SE. J. Hort is a member of the advisory boards of Alzheon and Agora. H. Kvartsberg, M. Vyhnalek, and L. Boonkamp report no disclosures relevant to the manuscript. M. Novak reports no disclosures relevant to the manuscript and is a full-time employee of Axon Neuroscience SE, Cyprus. H. Zetterberg has served on scientific advisory boards for Denali, Roche Diagnostics, Samumed, CogRx, and Wave; has given lectures in symposia sponsored by Fujirebio, Biogen, and Alzecure; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg, all unrelated to the work presented. O. Hansson has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, AVID Radiopharmaceuticals, and Euroimmun; in the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. P. Scheltens has received consultancy/speaker fees (paid to the institution) from Biogen, People Bio, Roche (Diagnostics), and Novartis Cardiology; he is PI of studies with Vivoryon, EIP Pharma, IONIS, CogRx, AC Immune, and Toyama. K. Blennow has served as a consultant or at advisory boards for Abcam, Axon Neuroscience, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture–based platform company at the University of Gothenburg, all unrelated to the work presented in this article. C.E. Teunissen has collaboration contracts with ADx Neurosciences, Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen Prevention Center, Boehringer, Axon Neurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. N. Zilka reports no disclosures relevant to the manuscript; he is a full-time employee of AXON Neuroscience R&D Services SE. Go to Neurology.org/N for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Class of Evidence: NPub.org/coe

  • Received March 4, 2020.
  • Accepted in final form July 8, 2020.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. 1.↵
    1. Blennow K,
    2. Zetterberg H
    . Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med 2018;284:643–663.
    OpenUrl
  2. 2.↵
    1. Blennow K
    . CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005;5:661–672.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Blennow K,
    2. Hampel H
    . CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–613.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Molinuevo JL,
    2. Ayton S,
    3. Batrla R, et al
    . Current state of Alzheimer's fluid biomarkers. Acta Neuropathol 2018;136:821–853.
    OpenUrlPubMed
  5. 5.↵
    1. Jack CR Jr.,
    2. Bennett DA,
    3. Blennow K, et al
    . NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535–562.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Barthélemy NR,
    2. Bateman RJ,
    3. Marin P, et al
    . Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology. bioRxiv 2017.
  7. 7.↵
    1. Barthélemy NR,
    2. Mallipeddi N,
    3. Moiseyev P,
    4. Sato C,
    5. Bateman RJ
    . Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. Extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease. Front Aging Neurosci 2019;11.
  8. 8.↵
    1. Sato C,
    2. Barthélemy NR,
    3. Mawuenyega KG, et al
    . Tau kinetics in neurons and the human central nervous system. Neuron 2018;97:1284–1298.
    OpenUrl
  9. 9.↵
    1. Kontsekova E,
    2. Novak M,
    3. Kontsek P,
    4. Borecky L,
    5. Lesso J
    . The effect of postfusion cell density on establishment of hybridomas. Folia Biol 1988;34:18–22.
    OpenUrl
  10. 10.↵
    1. Andreasson U,
    2. Perret-Liaudet A,
    3. van Waalwijk van Doorn LJC, et al
    . A practical guide to immunoassay method validation. Front Neurol 2015;6.
  11. 11.↵
    1. van der Flier WM,
    2. Scheltens P
    . Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis 2018;62:1091–1111.
    OpenUrl
  12. 12.↵
    1. McKhann GM,
    2. Knopman DS,
    3. Chertkow H, et al
    . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–269.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Gorno-Tempini ML,
    2. Hillis AE,
    3. Weintraub S, et al
    . Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–1014.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Höglinger GU,
    2. Respondek G,
    3. Stamelou M, et al
    . Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32:853–864.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Armstrong MJ,
    2. Litvan I,
    3. Lang AE, et al
    . Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Vanderstichele H,
    2. Bibl M,
    3. Engelborghs S, et al
    . Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65–73.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Engelborghs S,
    2. Niemantsverdriet E,
    3. Struyfs H, et al
    . Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement 2017;8:111–126.
    OpenUrl
  18. 18.↵
    1. Pepe MS,
    2. Pepe PBMS
    . The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003.
  19. 19.↵
    1. DeLong ER,
    2. DeLong DM,
    3. Clarke-Pearson DL
    . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Hedges LV,
    2. Olkin I
    . Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press; 1986.
  21. 21.↵
    1. Gayen AK
    . The frequency distribution of the product-moment correlation coefficient in random samples of any size drawn from non-normal universes. Biometrika 1951;38:219–247.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Alafuzoff I,
    2. Arzberger T,
    3. Al-Sarraj S, et al
    . Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008;18:484–496.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Janelidze S,
    2. Stomrud E,
    3. Smith R, et al
    . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun 2020;11.
  24. 24.↵
    1. Barthelemy NR,
    2. Hirtz C,
    3. Lehmann S, et al
    . Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther Alzheimer's Res Ther 2020;12.
  25. 25.↵
    1. Lippa CF,
    2. Ozawa K,
    3. Mann DMA, et al
    . Deposition of β-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol 1999;56:1111–1118.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Cirrito JR,
    2. Kang J-E,
    3. Lee J, et al
    . Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008;58:42–51.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Yamada K,
    2. Holth JK,
    3. Liao F, et al
    . Neuronal activity regulates extracellular tau in vivo. J Exp Med 2014;211:387–393.
    OpenUrlAbstract/FREE Full Text

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me